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  2015	  
 
Background:  This dissertation involves an evaluation of the effect of the Patient 
Protection and Affordable Care Act (ACA) on diabetic medication adherence as the 
Medicare Part D coverage gap begins to close.  
Purpose:  The dissertation’s primary research question: will medication 
adherence for Humana Medicare Part D health plan members filling diabetic medications 
at Humana’s mail order pharmacy improve as the coverage gap is incrementally closed 
due to the ACA? The study had 3 objectives: 1) to evaluate diabetes medication 
adherence of health plan members before they reach the coverage gap and then while 
they are in the coverage gap, 2) to compare diabetes medication adherence between two 
similar groups with differing benefit structures, one group with a gap in coverage as 
opposed to a group with no benefit changes within the year and 3) to examine diabetes 
medication adherence trend over multiple years as the coverage gap is closed. 
Methods: A retrospective, pre-post cohort analysis with control group study 
design was used to assess the study objectives. The control group consisted of low- 
vi	  
income subsidy (LIS) members with no gap in coverage and the treatment group reached 
the coverage gap. 
Results: Brand and generic medication users exhibited decreases in adherence 
once they entered the coverage gap although significant differences were seen for all 
years in the brand cohort only. The control group exhibited better adherence than the 
treatment group. The control group also exhibited stable adherence year over year while 
the treatment group realized a decline. 
Conclusions: The results of this study indicate that being in the coverage gap was 
a significant indicator of a decrease in adherence for health plan members on brand 
diabetic medications. While the study findings showed a decrease rather than an increase 
in the treatment group medication adherence year over year, the results did indicate no 
significant changes in the control group. The expectation would be that once the coverage 
gap is fully closed in 2020, the treatment group would exhibit similar behavior.  Both 
groups exhibited high adherence overall suggesting the mail order dispensing channel 
could have an effect on adherence. 
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Background to the Study 
Former Attorney General C. Everett Koop said, “Drugs don’t work in patients 
who don’t take them (P. Ho, Bryson, & Rumsfeld, 2009).” Compliance, adherence and 
persistence are terms commonly used to describe the patient’s reaction to medical advice 
or instruction (Bailey & Kodack, 2011). Compliance describes a patient’s willingness to 
follow a prescribed treatment regimen. Adherence, however, is the extent to which the 
patient achieves an agreed upon treatment regimen without close supervision. Persistence 
is the duration of time from initiation to discontinuation of therapy. Poor medication 
adherence accounts for substantial deterioration of disease, death and increased health 
care costs in the United States. Of all medication-related hospital admissions in the 
United States, 33 to 69 percent result from poor medication adherence, with an estimated 
cost of $100 billion a year (Osterberg & Blaschke, 2005).  
Adherence to medication regimens has been observed since the time of 
Hippocrates, when the effects of various potions were recorded with notations of whether 
the patient had taken them or not (Osterberg & Blaschke, 2005). There are many ways to 
measure medication adherence that involve both direct and indirect methods.  Direct 
methods include directly observed medication administration and detection of medication 
levels in the blood while methods with indirect measurement are patient questionnaires, 
pill counts and rate of refills (Osterberg & Blaschke, 2005).   
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Medication non-adherence is a multifaceted issue that relates to both behavioral 
and system barriers (Touchette & Shapiro, 2008). Behavioral barriers include social 
support, cognition and personal health beliefs. System barriers include treatment 
complexity (multiple medications/dosing schedule), system complexity (multiple 
providers) and cost. 
 
The Importance of Adherence in Public Health 
The impact of poor medication adherence has an impact to the population in terms 
of both health and cost.  In 2009, a research brief by the New England Healthcare 
Institute estimated that medication non-adherence, in addition to suboptimal prescribing, 
drug administration and diagnosis could result in as much as $290 billion per year in 
avoidable medical spending, equivalent to 13 percent of total U.S. health care 
expenditures (New England Healthcare Institute, 2009). While a report released by 
Express Scripts in 2014 estimated the cost at $337 billion, which equates to about one of 
every nine healthcare dollars spent wasted due to non-adherence (Sundar, 2015). In fact, 
non-adherence to prescribed medication regimens has been shown to result in $100 
billion in costs related to excess hospitalizations alone (New England Healthcare 
Institute, 2009) and accounts for as many as 40 percent of nursing home admissions 
(Case Management Society of America, 2006). Clearly, poor adherence can lead to an 
increase in acute healthcare resource utilization and result in the need for specialized and 
costly long-term care.  
In addition to the cost burden that medication non-adherence places on the 
healthcare system, it can also be a cause of mortality. An analysis conducted in England 
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attributed medication non-adherence to be a contributing factor in at least 25 percent of 
suicides and homicides by people with mental illness (Priebe et al., 2010). It also is 
estimated that a lack of adherence to regimens for heart disease is responsible for 125,000 
deaths annually (McCarthy, 1998).  
The adverse effects of poor adherence are both individual and societal (Giuffrida 
& Torgerson, 1997). Non-adherence reduces the benefit of the preventive or curative 
services of the therapy to the individual. The lack of adherence may cause unnecessary 
diagnostic and treatment procedures, adding cost to the system and for the patient. Non-
adherence to treatment for infectious disease can result in drug resistance and spread of 
infection to others. This is especially relevant in the treatment of tuberculosis, a serious 
public health concern. Poor adherence leads to more expensive treatment for the 
individual patient as the disease progresses and increases the possibility of drug 
resistance and threat of infection to the population at large. Another public health 
example would be adherence to anti-rejection medications following organ 
transplantation. Organs are a scare resource and when protocols are not followed, those 
resources are wasted. In fact, a study in the 1980’s showed 18 percent of post-transplant 
patients were non-adherent (Burns & Shaw, 2007). Of those 18 percent a majority (91 
percent) lost the transplanted organ or died compared to 18 percent of patients in the 
adherent group. Finally, non-adherence by individuals in clinical trials can result in 
overestimations of therapeutic dosing, causing drug toxicity in adherent patients. 
Although medication adherence has clear benefits to society and the individual, 
the choice to be adherent lies primarily with the individual. Some reasons a person might 
choose to be non-adherent to therapy include a decision to avoid potential serious side 
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effects or on the basis that the patient disagrees with the treatment or even the diagnosis 
itself (Priebe et al., 2010). There are potential benefits to non-adherence because it can 
sometimes reduce the cost of treatment and adverse effects, especially if the treatment is 
inappropriate (Giuffrida & Torgerson, 1997).  
There are numerous barriers to adherence, many of which the patient may have no 
control over. The World Health Organization (WHO) defines five categories of 
medication related non-adherence (P. Ho et al., 2009). The first category is the health 
system, which could include a lack of access to providers, poor communication between 
the patient and provider or even a language barrier. The type of condition the patient has 
is often a barrier to adherence. Patients who have diseases with no symptoms or physical 
cues may have a difficult time remembering to take their medication. Patients who suffer 
from mental illness may take their medications, start to feel better and stop taking it, 
cycling through phases of adherence and non-adherence. The patient themself can be a 
barrier to adherence. Studies have shown that adherence is lower in younger patients and 
those of nonwhite race. Older patients may have mental impairments that hinder their 
ability to be adherent or dexterity issues that would prohibit them from something as 
simple as opening a child-protective bottle. The fourth category is therapy. For example, 
patients on multiple drugs or drugs that require multiple doses a day are less likely to be 
fully- adherent. Finally, a patient’s socioeconomic status can act as a barrier to adherence.  
Low health literacy can result in an inability to understand directions on how or when to 
take the medication and higher medication costs can hinder the patient’s ability to even 
obtain the medication on a regular basis.  
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Table 1. WHO categories of non-adherence (P. Ho et al., 2009) 
Categories of  
non-adherence 
Examples 
Health System Poor quality of provider-patient relationship; poor communication; 
lack of access to healthcare; lack of continuity of care 
Condition Asymptomatic chronic disease (lack of physical cues); mental 
health disorders (e.g. depression) 
Patient Physical impairments (e.g. vision problems or impaired dexterity); 
cognitive impairment; psychological/behavioral; younger age; 
nonwhite race 
Therapy Complexity of regimen; side effects 
Socioeconomic Low literacy; higher medication costs; poor social support 
 
The Importance of Adherence in Diabetes 
Medication adherence is especially important for chronic diseases like diabetes, 
where medication can prevent or delay the onset of complications, reduce hospitalization 
risks and costs and improves quality of life for patients (Sacks, Burgess, Cabral, Pizer, & 
McDonnell, 2013). Diabetes is increasingly common among seniors, with prevalence 
rates estimated at 26.7 percent and roughly 390,000 cases diagnosed annually (Sacks et 
al., 2013). Generic medications are used as first-line and second-line therapies, with a 30-
day supply of metformin, a biguanide, and sulfonylureas (glimepiride, glipizide, 
glyburide) readily available as inexpensive $4 cash generics. Higher priced branded 
products like sitagliptin (marketed only as Januvia and not yet generically available), 
with average 30-day cash prescription prices exceeding $300, are recommended for more 
complex or advanced disease.  
The long-term complications of diabetes, particularly type 2 diabetes, present a 
difficult challenge that requires comprehensive management of glycemia and a myriad of 
cardiovascular (CV) risk factors and comorbidities (Bailey & Kodack, 2011). 
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Hemoglobin A1c (HbA1c) levels reflect the glucose concentration in the blood. A high 
glucose concentration equates to a higher HbA1c. Levels of HbA1c are not influenced by 
daily fluctuations in the blood glucose concentration rather reflect the average glucose 
levels over the prior six to eight weeks. Therefore, HbA1c is a useful indicator of how 
well the blood glucose level has been controlled in the recent past and may be used to 
monitor the effects of diet, exercise and drug therapy on blood glucose in diabetic 
patients. In healthy, non-diabetic patients the HbA1c level is less than 7 percent of total 
hemoglobin. It has been demonstrated that the complications of diabetes can be delayed 
or prevented if the HbA1c level can be kept close to 7 percent (American Diabetes 
Association, 2015). In general, values should be kept below 8 percent. 
Although an extensive and effective range of medications options exist to address 
these issues, only slightly more than half of patients achieve a HbA1c target of less than 
7.0 percent and about two-thirds of patients die of CV disease (Bailey & Kodack, 2011). 
There are established protocols, guidelines and algorithms to accommodate the needs of 
most patients under a majority of circumstances. However, medication adherence is often 
a neglected issue in this patient population. Table 2 outlines the available therapies used 
to manage Type 2 diabetes, the initial dose and the approximate cash price for a 30-day 
supply as of June 2015. 
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Table 2. Drugs for Type 2 Diabetes (Pharmacist's Letter/Prescriber's Letter, June 2015) 




Acarbose (Precose, others) 
 
Miglitol (Glyset) 
Acarbose: 25mg PO TID ($45) 
 
Miglitol: 25mg PO TID ($145) 
Amylin analog Pramlintide (Symlin) Pramlintide: 60mcg SC prior to major meals 
($590) 
Biguanide Metformin (Glucophage, 
Glucophage XR) 
Metformin: 500mg PO BID or 850mg PO once 
daily (less than $20/month) 
Dipeptidyl 
peptidase-4 (DPP-
4) inhibitor or 
incretin enhancer 
Alogliptin (Nesina) 
With metformin (Kazano) 
With pioglitazone (Oseni) 
 
Linagliptin (Tradjenta) 









With metformin (Janumet, 
Janumet XR) 
With simvastatin (Juvisync) 













Sitagliptin: 100 mg PO once daily ($330) 
Glucagon-like, 
peptide-1 (GLP-1) 












Albiglutide: 30mg SC once weekly ($325)  
 
Dulaglutide: 0.75mg SC once weekly ($490) 
 
Exenatide: 5mg SC BID ($480) 
 
Exenatide extended-release: 2mg SC once weekly 
($475) 
 
Liraglutide: 0.6mg SC daily x 1 week then 1.2mg 
SC once daily ($430) 
Insulin Rapid-acting insulin: lispro 
(Humalog), aspart (NovoLog), 
glulisine (Apidra) 
 
Regular short-acting insulin: 
Humulin R, Novolin R 
 
Intermediate-acting (basal) 
insulin: NPH (Humulin N, 
Novolin N)  
 
Long-acting (basal) insulin: 











Rapid acting: NovoLog Mix 
70/30, Humalog Mix 75/25 or 
50/50  
Short-acting: Humulin 70/30, 
Novolin 70/30 
Varies 
Meglitinide Nateglinide (Starlix) 
 
Repaglinide (Prandin, others) 
With metformin (PrandiMet) 
Nateglinide: 60 to 120mg PO TID ($105) 
 











With linagliptin (Glyxambi) 
Canagliflozin: 100mg PO once daily ($340) 
 
 
Dapagliflozin: 5mg PO once daily ($340) 
 






Tolazamide (Tolinase, others) 
 
Tolbutamide (Orinase, others) 
Chlorpropamide: 100 to 200mp PO once daily 
(less than $20/month) 
 
Tolazamide: 250mg PO once daily ($48) 
 
Tolbutamide: 1g PO once daily ($70) 
Sulfonylurea-
second generation 
Glyburide (Diabeta, Glynase, 
Micronase, others) 
With metformin (Glucovance) 
 
Glipizide (Glucotrol, 
Glucotrol XL, others) 
 
Glimepiride (Amaryl, others) 
With metformin (Amaryl M) 
With pioglitazone (Duetact) 
With rosiglitazone 
(Avandaryl) 




Glipizide: 5mg PO once daily (less than 
$10/month) 
 







Pioglitazone  (Actos) 
With metformin (ActosMet, 
ActosMet XR) 
With glimepiride (Duetact) 
With alogliptin (Oseni) 
 
Rosiglitazone  (Avandia) 
With metformin (Avandamet) 
With glimiperide (Avandaryl) 






Rosiglitazone: Initial 4mg PO once daily ($115) 
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Extensive evidence indicates that rigorous control of blood glucose is associated 
with a reduction in long- term vascular complications in patients with type 2 diabetes 
(Bailey & Kodack, 2011). Greater adherence to treatment regimens has shown to improve 
metabolic control outcomes. Indeed, non-adherent patients are at increased risk for the 
development of vascular complications, hospitalizations and death. Researchers 
conducting a study of adherence in a medically indigent population with type 2 diabetes 
noted that each 10 percent decrease in adherence was accompanied by a positive 0.14 
percent increase in HbA1c (Bailey & Kodack, 2011). In addition, the benefits of 
improved adherence have been linked to fewer emergency department visits and fewer 
inpatient admissions. Patients with diabetes who did not regularly take their diabetes 
medications as prescribed were 2.5 times more likely to be hospitalized than those who 
were adherent more than 80 percent of the time (Lau & Nau, 2004). 
 





The Medicare Modernization Act of 2003 
The Medicare Modernization Act (MMA) of 2003 allowed Medicare expansion in 
2006 to offer voluntary outpatient prescription drug coverage ("The Medicare 
Prescription Drug Benefit Fact Sheet," 2014). All 54 million people on Medicare are 
eligible to enroll in this benefit offered through private plans approved by the federal 
government. The Medicare drug benefit is offered through stand-alone prescription drug 
plans (PDP) covering only outpatient medications and Medicare Advantage prescription 
drug (MAPD) plans covering all Medicare benefits including drugs. 
Enrollment in Medicare drug plans is voluntary, with the exception of those who 
are dually eligible for both Medicare and Medicaid and certain other low-income health 
plan members who are automatically enrolled in a PDP if they do not choose a plan on 
their own ("The Medicare Prescription Drug Benefit Fact Sheet," 2014).  In 2014, more 
than 37 million Medicare health plan members were enrolled in Medicare Part D plans, 
up from 26 million in 2009.  Of this total, about two-thirds were enrolled in a stand-alone 
PDP and one-third enrolled in a Medicare Advantage drug plan. 
A unique feature to the Medicare Part D benefit is the coverage gap, sometimes 
referred to as the “donut hole”. The coverage gap was included because the cost of 
providing continuous coverage with no gap would have exceeded the budgetary limit 
imposed on the legislation when the Medicare drug benefit was established (Hoadley, 
Thompson, Hargrave, Cubanski, & Neuman, 2008). The coverage gap is a benefit phase 
where the enrollee incurs all or most of the drug cost until they hit a certain dollar limit. 
The Medicare health plan members who are eligible for a low-income subsidy or dually 
eligible for both Medicare and Medicaid are not subject to the coverage gap.  
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In 2013, most PDPs (69 percent) offered little or no gap coverage beyond that 
required by law (Hoadley, Summer, Hargrave, & Cubanski, 2013). The plans offering 
extra gap coverage have premiums that are almost twice as expensive as those that offer 
no coverage and therefore fewer enrollees. In fact, enrollment in these plans has remained 
low since 2006 with only 5-6 percent of PDP enrollees choosing a plan that includes 
some type of coverage in the gap. In 2013, only 35 percent of MAPD enrollees were in a 
plan that had extra gap coverage, which was up from 27 percent in 2006. 
 
The Patient Protection and Affordable Care Act 
In 2010, the Patient Protection and Affordable Care Act (ACA) made significant 
changes to the coverage gap. Table 3 outlines the benefit phases, coverage limits and 
coverage gap changes from 2009 to 2014. Standard Part D Plans have a deductible phase, 
followed by an initial coverage phase where the enrollee pays 25 percent of the drug cost 
up to a set coverage limit. The enrollee then enters the coverage gap, where until 2010 the 
enrollee was responsible for 100 percent of the drug costs until they entered the 
catastrophic phase. The ACA mandates that the coverage gap will incrementally close 
until it is eliminated in 2020.  
Figure 2. Medicare Part D Benefit Phases 
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Among Part D enrollees who used prescription drugs in 2009 and did not receive 
a low-income subsidy, about one in five (19 percent) had spending high enough to reach 
the coverage gap (Hoadley, Summer, Hargrave, & Cubanski, 2011). Overall, about 3.4 
million health plan members (12 percent of the total population of Part D enrollees) 
reached the coverage gap and faced the full cost of their prescription drugs in 2009. 
 










2009 2010 2011 2012 2013 2014 
Deductible Member Pays $295 $310 $310 $320 $325 $310 
Initial 
Coverage 
Member Pays 25% 25% 25% 25% 25% 25% 
Plan Pays 75% 75% 75% 75% 75% 75% 
Coverage 




Member Pays 100% 100% 50% 50% 47.5% 47.5% 
Plan Plays 0% 0% 0% 0% 2.5% 2.5% 
Manufacturer 
Pays 0% $250 50% 50% 50% 50% 
Generic Drugs 
Member Pays 100% 100% 93% 86% 79% 72% 
Plan Pays 0% 0% 7% 14% 21% 28% 
Coverage 
Limit $6,154 $6,440 $6,484 $6,730 $6,955 $6,691 
Catastrophic 
Coverage 
Member Pays 5% 5% 5% 5% 5% 5% 
Plan Pays 15% 15% 15% 15% 15% 15% 
Medicare 
Pays 85% 85% 85% 85% 85% 85% 
*Coverage Limit amount is Total Drug Costs (Plan paid + Health Plan Member paid) 
 
The Effect of Cost-Sharing and Copayments on Adherence 	  
 Patterson, et al. examined the association of higher copayments to a greater risk of 
non-adherence specifically targeting beta blocker utilization in heart failure patients 50 
years and older (Patterson, Blalock, Smith, & Murray, 2011). From a database of 38 
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million unique individuals, the researchers pared down the cohort to 2,359 relatively 
compliant heart failure patients.  
 The researchers found that patients with the highest copayment level ($26-30) as 
compared with the lowest copayment level (under $1) had on average a 7 percent less 
medication supply of beta-blockers over the course of a year. The researchers also found 
that patients with the higher copayment tier showed an increased risk of non-adherence. 
This study did have several limitations including a small sample size in the upper limit 
copayment tier and selection factors that could not be controlled.  
 Li, et al. and Zhang, et al. conducted studies that examined cost as a barrier to 
adherence when Medicare Part D patients reach the coverage gap and incur 100 percent 
cost share of their medications (Li, McElligott, Bergquist, Schwartz, & Doshi, 2012; 
Zhang, Baik, & Lave, 2013). Researchers in both studies utilized a pre-post design and a 
5 percent sample of Medicare health plan members. Li, et al. looked specifically at 
patients with hypertension and hyperlipidemia. They utilized a control group of low-
income subsidy patients who would have no benefit changes in the gap phase. The other 
three groups consisted of patients with no coverage in the gap, those with generic only 
coverage and patients with brand and generic coverage in the gap. 
 While in the coverage gap, patients in the no-coverage group had higher average 
out-of-pocket costs per prescription ($31 for anti-hypertensives and $79 for lipid-
lowering drugs), as did those in the generic-only coverage group ($29 for anti-
hypertensives and $58 for lipid-lowering drugs). The remaining groups had no substantial 
change in copayments. Compared to the control group, the no-coverage group had a 
statistically significant decrease in the number of brand and generic prescriptions, which 
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would translate to a decrease in adherence. The generic-only coverage group had a 
statistically significant decrease in brand prescriptions but not adherence to generic 
prescriptions. 
Zhang, et al. examined a population with heart failure and/or diabetes through the 
coverage gap. As in the prior study, a low-income subsidy group was utilized as a control 
but only 2 other groups were identified: no coverage through the gap and generic only 
coverage. Researchers utilized propensity score matching for age, sex, race and number 
of Elixhauser comorbidities. The Elixhauser comorbidity index is a measurement tool 
that defines 30 comorbid (i.e., co-existing) conditions using ICD-9 codes. This 
instrument was developed in order to be used with large administrative data sets 
(Elixhauser, Steiner, Harris, & Coffey, 1998). 
The study conducted by Zhang, et al. had three important findings. First, when 
matched to the comparison group, there were statistically significant reductions in all 
studied outcomes present in both study groups: probability of using a drug, mean number 
of monthly prescriptions filled and monthly pharmacy spending. However, the no-
coverage group showed a greater decrease in medication adherence than those with 
generic drug coverage only in the gap. Second, the overall decrease in monthly 
medications amounts and spending was primarily due to a decrease in brand medication 
utilization. For example, those without drug coverage in the gap reduced their overall 
medication use by 0.85 medications per month (75 percent brand name/25 percent 
generic). This group decreased its monthly pharmacy spending by $73.15 ($66.65 brand 
name/$6.40 generic). Third, those with generic only coverage in the gap reduced their use 
of brand-name drugs but did not compensate for the decrease by increasing their use of 
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generic drugs. In fact, they also decreased their use of generic drugs slightly but 
negligibly.  
 These studies are significant because they establish a relationship between cost 
and medication adherence. In fact, researchers of a 2004 RAND study found that 
doubling copayments for medications reduced adherence by 25 to 45 percent (Goldman, 
2004). As patients’ use of medications declined due to increased copayments, emergency 
room visits increased 17 percent and hospital stays rose 10 percent among patients with 
chronic conditions such as diabetes, asthma or gastric acid disorder. 
 
Proposed Reform Effects 
 In 2013, two studies were published with focus on what may happen to adherence 
for patients on anti-diabetic medication when the coverage gap closes (Sacks et al., 2013; 
Zeng, Patel, & Brunetti, 2013). Researchers in both studies share the hypothesis that 
closing the coverage gap thereby decreasing costs for patients will result in better 
medication adherence. The Zeng, Patel & Brunetti study analyzed 2 cohorts of patients: 
one group before any reform measures were enacted in 2010 and one group when brand 
drugs were covered at 50 percent through the gap in 2011. Pharmacy claims data was 
used for analysis and medication adherence was measured by portion of days covered 
(PDC). 
 Zeng, et al, found that the average copayment in the coverage gap decreased by 
27 percent from 2010 to 2011 and patients with no coverage or partial coverage in the 
gap showed improved medication adherence in 2011 over 2010. However, patients with 
full coverage in the gap showed unchanged adherence year over year. 
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 Sacks, et al. utilized 2 cohorts consisting of low income and non-low income 
while logistic regression was used to model the likelihood of adherence to oral anti-
diabetic medications. The researchers concluded that the elimination of the coverage gap 
would not affect generic utilization but should increase adherence for those who utilize 
brand medications. 
 In 2012, a poster titled “Impact of the Affordable Care Act on Medication 
Adherence in a Population of Medicare Part D Beneficiaries” was presented at the 
Academy for Managed Care Pharmacy (AMCP) conference (Brown, Ward, & Yihua, 
2012). The objectives of the study were to assess the impact of changes in the Medicare 
Part D Coverage gap on adherence to brand and generic medications across plan years. 
The researchers looked at Humana Medicare Part D health plan member utilization of 
diabetic and anti-platelet medications between 2009 and 2012. They found the ACA is 
modestly improving adherence across plan years and during the Medicare coverage gap 
for brand medications while adherence to generic diabetes medications showed no 
significant improvement. 
 
Statement of the Problem 
 Prior research has been conducted on associations between medication adherence 
and copayment levels in the Commercially insured population (Patterson et al., 2011). 
Researchers have also studied the effect of the Part D coverage gap on medication 
adherence (Li et al., 2012; Zhang et al., 2013) and how proposed coverage gap reform 
may influence adherence (Sacks et al., 2013; Zeng et al., 2013). However, little research 
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has been published regarding the ACA’s effect on medication adherence in the coverage 
gap utilizing actual claims data.  
 
Purpose of the Study 
 The main goal of this study is to examine how a public policy can affect 
medication adherence in a subset of a population. In order to achieve this goal, the study 
has 3 objectives: 1) to evaluate diabetes medication adherence of health plan members 
before they reach the coverage gap and then while they are in the coverage gap, 2) to 
compare diabetes medication adherence between two similar groups with differing 
benefit structures, one group with a gap in coverage as opposed to a group with no 
benefit changes within the year and 3) to examine diabetes medication adherence trend 
over multiple years as the coverage gap is closed.  
 Medication adherence is the primary outcome measure of this study. Adherence 
will be calculated by examining pharmacy claims data and using portion of days covered 
(PDC), which is the method endorsed by the Pharmacy Quality Alliance (PQA) (Nau). If 
a health plan member has enough medication to cover 80 percent of the measurement 
period, that health plan member will be considered adherent. Based on numerous studies 
of the relationship of medication adherence and healthcare outcomes, PQA selected 0.8 
(or 80 percent) as the threshold above which the patient can be considered to be adherent 
for most classes of chronic medications. 
 To the best of my knowledge, this is one of only a handful of studies to utilize 
real-world claims data to examine the affect of the ACA on medication adherence in the 
18	  
Medicare Part D coverage gap. The study also provides the opportunity to add to the 
wealth of literature around cost related non-adherence in the Medicare population.  
 
Research Question and Hypotheses 
Will medication adherence for Humana Medicare Part D health plan members 
filling diabetic medications at Humana’s mail order pharmacy improve as the coverage 
gap is incrementally closed due to the Patient Protection and Affordable Care Act 
(ACA)? 
Research Hypothesis 1: Diabetes medication adherence will decrease when health 
plan members are in the coverage gap. 
Null Hypothesis 1: There will be no change to diabetes medication adherence 
when a health plan member enters the coverage gap. 
Research Hypothesis 2: Diabetes medication adherence of the control group will 
be better than the study group. 
Null Hypothesis 2: There will be no statistically significant difference in 
medication adherence between the groups.  
Research Hypothesis 3: Diabetes medication adherence in the coverage gap will 
show significant improvement for brand drugs year over year as the coverage gap closes. 
Null Hypothesis 3:  Diabetes medication adherence will not show significant 
improvement for brand drugs. 
Research Hypothesis 4: Diabetes medication adherence in the coverage gap will 
show slight improvement for generic drugs year over year as the coverage gap closes. 
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Null Hypothesis 4: Diabetes medication adherence will not show slight 
improvement for generic drugs. 
 
Summary 
Medication adherence is an essential part of managing chronic disease. Poor 
medication adherence results in additional costs to the healthcare system, a decreased 
quality of life for the patient and can even result in death. For patients with diabetes, 
medication adherence plays a vital role in managing blood glucose levels. Specifically, it 
has been documented that each 10 percent decrease in adherence was accompanied by a 
positive 0.14 percent increase in HbA1c. Furthermore, diabetic patients who did not 
regularly take their diabetes medications were 2.5 times more likely to be hospitalized 
than those who followed their prescribed treatment regimens more than 80 percent of the 
time. 
Medicare is a federal insurance program established in 1965 providing health 
insurance to Americans ages 65 and older and to individuals under age 65 with specific 
disabilities or end-stage renal disease. In order to increase Medicare health plan 
members’ access to medications and help lower their prescription drug costs, the 
Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 
introduced a prescription drug benefit referred to as ‘Medicare Part D’. Medicare Part D 
has been structured to include substantial cost sharing by way of deductibles, co-
payments and coinsurance. 
A significant amount of research has been dedicated to understanding the impact 
of cost sharing on prescription drug utilization, medication adherence and health 
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outcomes. A review of the literature indicates that cost sharing has also been associated 
with decreased medication adherence, increased costs and increased out-of-pocket 
expenses for health plan members. As the coverage gap closes, it provides a unique 
opportunity to examine the effect of lessening the cost burden on medication adherence. 
Details of the theoretical framework used to assess the study objectives are provided in 
Chapter 2.




The objectives in this study will be analyzed using the framework provided by the 
economic theory and Andersen's Behavioral Model of Health Services Use. Both theories 
offer a framework by which to examine health services utilization with respect to cost 
and other variables. The economic theory points toward cost as a driver for behavior 
while Andersen’s model includes a range of factors and feedback loops that ultimately 
affect health care use and subsequent outcomes. 
 
Economic Theory 
Economic theory postulates that, when a patient is charged the full price of a 
prescription medication and has adequate information to weigh the medication’s benefits 
versus adverse effects, they will consume an optimal amount of the medication, given 
their priorities and income constraints (Gibson, Ozminkowski, & Goetzel, 2005). The 
theory assumes that rational patients will evaluate both the costs and benefits of a 
medication compared with other methods of producing health and will utilize 
combinations of these that maximize their health with respect to their income limitations. 
It is possible that a patient who obtains insurance coverage that includes a 
prescription benefit may be motivated to consume more medications than normal once 
the cost barrier is removed and the price to the patient is lower than full price (Gibson et 
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al., 2005). Therefore, raising the price of the medication through higher levels of cost 
sharing can have various economic and behavioral effects. 
Increasing cost to the patient can result in a change in consumption. As cost 
sharing shifts to the patient, the patient moves up the demand curve and closer to the 
economically optimal amount (Gibson et al., 2005). This ultimately results in a reduction 
in consumption of medication. In terms of this study, as patients move into the coverage 
gap and bear the full cost of the medication, it would be reasonable to expect some 
patients to change their utilization patterns. For example, a patient could change 
consumption from taking a medication twice daily as prescribed to once daily.  In this 
study, medication adherence for the health plan members was calculated prior to reaching 
the coverage gap and then while in the coverage gap to look for a change in medication 
utilization and consumption. 
Another economic effect as a result of higher costs is substitution. Patients are 
likely to search for less expensive substitutes as the prices of prescription medications 
rise (Gibson et al., 2005). Therefore, if they discover a suitable substitute, patients are 
likely to consume smaller quantities of prescription medications and larger quantities of 
the substitute. Patients who utilize brand name medications may consider switching to a 
generic alternative or over the counter product once they reach the coverage gap. 
An increase in cost to the patient may cause them to consider the value of the 
medication. A price increase would decrease the likelihood that drugs of low value, for 
which the cost exceeds the perceived benefit to the patient, would be used (Gibson et al., 
2005). Conversely, patients would be price insensitive for high-value drugs, such as those 
that are perceived as life sustaining, and would be expected to continue to fill 
23	  
prescriptions. However, this assumes that consumers have adequate information to 
evaluate both the benefits and costs of drugs, which this study will lack sufficient data to 
establish. 
 
Andersen's Behavioral Model of Health Services Use  
Andersen's Behavioral Model of Health Services Use was originally developed in 
1968 and has since been modified multiple times (Andersen, 1995). The foundation of 
the model lies in the premise that outcomes are dependent on environment factors, 
population characteristics and health behavior factors. The 1995 modified model, as 
shown below, is most frequently used in studies assessing health services use. 
 
Figure 3. Andersen’s Behavioral Model of Health Service Use (Andersen, 1995) 
 



























 Environment factors, not present in the initial model, are an important input for 
understanding the use of health services and refer to a combined measure of health care 
system factors and external environment factors (Andersen, 1995). Health care system 
factors include dynamics related to accessible health care resources, their organization in 
the health care system that impact health services use and national health policy. External 
environment factors refer to physical, political and economic components in a health care 
system that impact use of health care services. 
Population characteristics signify predisposing factors, enabling resources and 
need (Andersen, 1995). Predisposing factors involve demographic variables (age, gender) 
that represent biological imperatives suggesting the likelihood that people will need 
health services and social structure (education, marital status, race/ethnicity, occupation) 
that determine the status of a person in the community, ability to cope with health 
problems and capacity to control resources to deal with health issues. An individual’s 
health beliefs are also a predisposing factor. Health beliefs are attitudes, values and 
knowledge that people have about health and health services that influence their 
perception of need and use of health services. Enabling resources include accessibility 
and availability of family and community resources such as income, health insurance, a 
regular source of care, travel to services and waiting times. Need factors refer to both 
perceived and evaluated need. Perceived need is an individual’s judgments of their health 
status, how they experience symptoms of illness and whether or not they judge their 
problems to be of sufficient magnitude to seek professional help. Evaluated need 
represents professional judgment about that person’s health status and the need for 
medical care. 
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Health behavior factors represent a compound measure of personal health 
practices such as diet and exercise interacting with the use of formal health services 
including type, site, purpose and coordinated services in an episode of illness (Andersen, 
1995). 
Outcomes include perceived and evaluated health status and consumer 
satisfaction (Andersen, 1995). Perceived health status reflects the health status, as 
understood by the population itself while evaluated health status refers to the health status 
as evaluated by professionals. Consumer satisfaction is a clear outcome of health services 
including convenience, availability, financing, provider characteristics and quality of 
care. The feedback loops in the model reflect the dynamic and recurrent nature of a health 
services model.  
A major contribution of Andersen’s model is the proposed measures of access. 
Andersen presents four concepts within access that can be viewed through the conceptual 
framework (Andersen, 1995). Potential access is the presence of enabling resources or 
those means that allow the individual to seek care. Realized access is the actual use of 
care. Equitable access occurs when demographic characteristics and need regulate who 
obtains healthcare services. Whereas, inequitable access is a result of social structure (e.g. 
ethnicity), health beliefs and enabling resources (e.g. income) determining who receives 
medical care. 
Andersen also introduces the concept of mutability of his factors (Andersen, 
1995). To be considered useful for promoting equitable access, a variable must be 
mutable or point to policy that might bring about behavior changes. For example, 
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demographic variables have low mutability since age cannot be altered to change 
utilization. Social structure is also low because ethnicity cannot be changed and 
occupational/educational status is not easily transformed. Health beliefs are assigned 
medium mutability because they can be altered and sometimes affect behavior change. 
The RAND corporation study (Goldman, 2004) changed a highly mutable factor by 
doubling copayments. This change resulted had a significant impact on health services 
utilization as medication adherence declined.  
Andersen’s model presents a broad framework of various factors that influence 
health services utilization. In theory, all variables described in the model would be 
measured to adequately assess health care utilization but this study utilizes pre-existing 
data from a database and data required to assess each variable is not readily available. For 
purposes of this study, the Andersen’s model framework serves as a theoretical guide to 
assess the impact of the Medicare Part D coverage gap on Medicare health plan 
members’ diabetic medication adherence, based upon the availability of the data. Figure 4 
illustrates the model with variables included in this study. 
Environment factors indicate a measure of external environment factors and 
health care system factors, such as national policy. In this study, the national policies of 
interest are the ACA and the Medicare Part D coverage gap limits set by the Center for 




Figure 4. Andersen’s Behavioral Model of Health Service Use (with variables used in 
this study) (Andersen, 1995) 
 
   
Predisposing factors, such as demographic variables were easily assessed in this 
study, including age, gender and race/ethnicity. Data representing social status, such as 
marital status, education, occupation, co-morbidities and an individual’s health beliefs 
and attitudes, were not available. The enabling resource considered in this study was 
prescription drug insurance, as an individual’s access to a prescription drug benefit might 
influence their medication utilization. Need factors refer to an individual’s perceptions of 
their health status and their need for medical care. While the data does not provide a 


































direct measurement of need factors, an individual’s choice to fill their diabetic 
medication might be reflective of their perception of their health status and their need for 
medical care. Therefore, filling diabetic medication in January of the respective plan year 
was used as a need factor in this study. 
Health behavior factors are a compound measure of an individual’s personal 
health practices and health services use. Information related to the health plan member’s 
personal health practices was not available in the data. However, the health behavior 
assessed in this study refers to an individual’s prescription refill behavior and medication 
adherence before they reach the coverage gap and while in the coverage gap phase of 
their benefit. While health behavior assessment reflects the desired outcome to be 
measured in this study, the data available for this study did not allow for measurement of 
the outcomes listed in Andersen’s health behavior model and were abridged at 
measurement of health services use, (i.e. medication adherence). 
The aim of this study was to assess the impact of the Medicare Part D coverage 
gap on medication adherence by using a methodologically sound research design 
theoretically guided by the economic theory and Andersen's Behavioral Model of Health 
Services Use. The goal of the research was to accurately identify when a health plan 
member enters the coverage gap, incorporate health plan pharmacy data, include a control 
group, account for confounding variables, use a validated measure of adherence and 
apply statistically sound techniques for data analyses. Details of the methods used to 
assess the study objectives are provided in chapter 3.




 A retrospective, pre-post cohort analysis with control group study design was 
used to assess the study objectives. The study objectives examined medication adherence 
of health plan members enrolled in a health plan with no prescription drug coverage 
during the coverage gap (study group) compared with that of health plan members 
enrolled in a plan with no coverage gap (control group). The study objectives also 
examined medication adherence of the study group before they enter the coverage gap 
and while they are in the coverage gap. Pharmacy claims data from a large managed care 
organization with over 7 million lives and spanning 50 states was utilized. Data was 
extracted for the period January 1, 2009 to December 31, 2014. All analyses were 
conducted utilizing SAS Enterprise Guide version 5.1. 
 
Population 
 The population of interest in this study consisted of Humana Medicare Part D 
health plan members who reached the coverage gap benefit phase and utilized Humana 
mail order pharmacy to fill diabetic medications between 2009 and 2014. It should be 
noted that Humana mail order does not offer auto-refill for Medicare members but does 
outreach to members to encourage a refill when eligible. The comparison group consisted 
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of Humana Medicare Part D health plan members who did not face a gap in coverage at 
any period during the study years and utilized Humana mail order pharmacy to fill 
diabetic medications. 
Study participants included Medicare health plan members enrolled in a Medicare 
Advantage prescription drug (MAPD) or Medicare Part D prescription drug (PDP) plan 
offered by Humana, Inc. In order to qualify for the study group, health plan members 
must have been enrolled in a plan that offered no coverage in the gap. In order to be 
considered for inclusion in the control group, health plan members must have been 
enrolled in a plan with no lapse in benefit (i.e., the coverage gap), such as Low Income 
Subsidy (LIS) Medicare Part D plans.  
Humana, Inc. is the second largest national insurer of Medicare Part D health plan 
members. Total Medicare Part D enrollment as reported by CMS for years 2007 and 2014 
is presented in Figure 5 (Medicare Payment Advisory Commission, 2015). During that 
















Health plan members were eligible for inclusion in the analysis if they had at least 
one prescription claim for a medication of interest at Humana’s mail order pharmacy 
during the month of January in plan years 2009, 2010, 2011, 2012, 2013 or 2014. The 
date of the first fill of a study medication during the intake period was defined as the 
index fill. 
Health plan members in the study group were Medicare Part D prescription drug 
plan (PDP) or Medicare Advantage (MAPD) health plan members aged 18 to 89 years at 
the beginning of the plan year with 12 months continuous enrollment in a plan year. 
Eligible health plan members must have reached the Medicare coverage gap between 
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April 1st and September 30th during the respective plan year. The April to September 
time period is used in order to measure medication adherence both pre-coverage gap and 
within the coverage gap. Eligible health plan members for the comparison group must 
have been enrolled in a low-income subsidy (LIS) PDP or MAPD plan that offered 
continuous benefits with no deductible or coverage gap phases. 
 Adherence to generic and brand medications was calculated separately. Generic 
formulations of the study drugs were identified using a generic product indicator (GPI) 
variable for each drug in each year of the database. Eligible health plan members had a 
fill of one or more of the study medications. The diabetes medications of interest include 
all medications listed in Table 2 with the exception of insulin. Adherence was calculated 
using the days supply field found on the pharmacy claim. Pharmacy claims data for 
insulin does not have a quantifiable days supply. Moreover, it is not possible to calculate 
a PDC for any medication taken on an as needed basis or with a variable dosage unit per 
day (McKenzie, Lenz, Gillespie, & Skradski, 2012). Injectable medications with a fixed 
unit dose were included.  
The disease of interest in this study was Type 2 diabetes but medical data was not 
available for all health plan members to confirm a diagnosis by way of medical claims. 
Daily management of Type 1 diabetes is managed by balancing insulin, diet and exercise 
(Mehta et al., 2015). Therefore, it was assumed that excluding insulin from the study 
medications limited the population to those diagnosed with Type 2 diabetes. 
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Description of study variables 
a) Independent Variable 
The independent variable in this study was the coverage gap status of individuals. 
The coverage gap status was evaluated at two levels: pre- gap and gap. Pre-coverage gap 
refers to the period before an individual hits the coverage gap and gap refers to the period 
during the coverage gap. 
 
Determination of benefit phases  
In order to assess whether a Medicare health plan member enters the coverage 
gap, total costs and true out-of-pocket (TrOOP) costs must be calculated. Total costs 
represent those associated with filling a prescription drug and include the amount the 
health plan pays and the amount a health plan member pays (co-pay or member 
responsibility amount) after filling a prescription drug.  
True out-of-pocket costs, on the other hand, include only costs incurred by the 
health plan member. TrOOP costs are the prescription drug costs that count toward the 
annual out- of-pocket threshold that health plan members must reach before the 
catastrophic drug benefit phase begins (Center for Medicaid and Medicare Services, 
2014). Payment that counts toward TrOOP includes the amount a person pays for covered 
prescriptions before the plan begins to pay (the deductible phase), the amount a person 
pays for each covered prescription after the plan begins to pay (copayments or 
coinsurance during initial coverage period) and payments made for a covered prescription 
while in the coverage gap. 
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Payments for TrOOP eligible costs can be made by any of the following (Center 
for Medicaid and Medicare Services, 2014): 
• The person enrolled in a Medicare drug plan (including payments from his 
or her Medical Savings Account [MSA], Health Savings Account [HSA], 
or Flexible Spending Account [FSA]) 
• Family of the health plan member or friends 
• Qualified State Pharmacy Assistance Programs (SPAPs) 
• Medicare’s Extra Help (low-income subsidy) 
• Most charities (unless they’re established, run, or controlled by the 
person’s current or former employer or union or by a drug manufacturer’s 
Patient Assistance Program operating outside Part D)	  
• Drug manufacturers providing discounts under the Medicare coverage gap 
discount program 
• Indian Health Service (IHS) 
• AIDS Drug Assistance Programs (ADAPs) 
The drugs must be on the plan’s formulary or treated as “on formulary” due to a coverage 
determination, exceptions process or appeal. The drugs must be purchased at an in-
network pharmacy or in accordance with the health plan’s out of network policy. 
Payments that do not count toward TrOOP costs include the drug cost share paid 
by the plan, monthly plan premiums paid by the health plan member, drugs purchased 
outside the U.S and its territories, drugs not covered by the plan, drugs that are excluded 
from the definition of Part D drug (even in cases where the plan chooses to cover them) 
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and over-the-counter (OTC) drugs (even in cases where the plan requires them for step 
therapy) (Center for Medicaid and Medicare Services, 2014). 
Payments do not count toward TrOOP if made by the following (Center for 
Medicaid and Medicare Services, 2014): 
§ Group health plans such as the Federal Employees Health Benefit Program 
(FEHBP) or employer or union retiree coverage  
§ Government-funded health programs such as Medicaid, TRICARE, Workers’ 
Compensation, the Department of Veterans Affairs (VA), Federally Qualified 
Health Centers (FQHCs), Rural Health Clinics (RHCs), the Children’s Health 
Insurance Program (CHIP), and black lung benefits  
§ Other third-party groups with a legal obligation to pay for the person’s drug 
costs  
§ Patient Assistance Programs (PAPs) operating outside the Part D benefit  
§ Other types of insurance  
For health plan members enrolled in standard Part D plans, the table below was 
used to determine benefit phases for the respective plan year. 
 
Table 4. 2009-2014 Medicare Part D Standard Benefit Model Plan Parameters, including 
True Out-Of-Pocket (TrOOP) amounts (Q1Group) 
Year Initial 
Deductible 






2009 $295 $2,700 $4,350 
2010 $310 $2,830 $4,550 
2011 $310 $2,840 $4,550 
2012 $320 $2,930 $4,700 
2013 $325 $2,970 $4,750 
2014 $310 $2,850 $4,550 
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The following methodology was used to assess whether a health plan member hit 
the coverage gap or moved on to catastrophic coverage: 
1) Total drug costs (drug cost + dispensing fee) were calculated for each health 
plan member. The next step involved determining health plan members who had total 
costs less than the total drug cost for coverage gap entry for the plan year and plan 
members who had total costs less than the threshold. For 2009, this amount was $2,700. 
Health plan members who had total costs less than $2,700 represented those who 
remained in the initial coverage limit. Health plan members who had total costs greater 
than $2,700 were those who hit the coverage gap. 
2) For health plan members with total drug costs greater than $2,700, their TrOOP 
costs were calculated. For plan year 2009, health plan members who incurred TrOOP 
costs less than or equal to $4,350 and health plan members who incurred TrOOP costs 
greater than $4,350 were identified. Health plan members with TrOOP costs less than or 
equal to $4,350 represented those who remained in the coverage gap through the entire 
year. Health plan members with TrOOP costs greater than $4,350 represented those who 
were covered under the catastrophic coverage limit. 
 
b) Dependent Variable or Outcome Measure 
 Medication adherence is the primary outcome measure of this study. Adherence 
was calculated using portion of days covered (PDC), which is the method endorsed by 
the Pharmacy Quality Alliance (PQA) (Nau). PDC is also the medication adherence 
measure used by CMS to assign stars to health plans from which quality bonus payments 
are calculated (Green, 2013). Based on numerous studies of the relationship of 
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medication adherence and healthcare outcomes, PQA selected 0.8 (or 80 percent) as the 
threshold above which the patient can be considered to be adherent for most classes of 
chronic medications, including diabetic medications.  
 
Steps and Assumptions considered for medication adherence calculation 
The following steps and assumptions were considered to calculate medication 
adherence: 
1) An adherence value was calculated for each Medicare health plan member. The pre-
gap PDC reflects adherence before a health plan member hits the coverage gap and the 
gap-PDC reflects adherence during the coverage gap. 
2) The day a health plan member’s total costs are equal to the coverage gap limit for that 
year, was considered as the day a health plan member hits the coverage gap. All 
prescriptions filled on the day a health plan member hits the coverage gap were 
considered as prescriptions filled after hitting the coverage gap. 
3) Medication adherence was calculated by using the health plan member’s January index 
fill as the start date and December 31st as the end date. 
4) If a health plan member’s days supply for their last fill was greater than the number of 
days in the calendar year, then the days supply was truncated to reflect the number of 
days left in the calendar year.  
5) The variable days supply associated with dosage forms such as an injectable (e.g. 
insulin) may result in incorrect estimates. Thus, as is frequently done in studies assessing 
medication adherence, only oral dosage and fixed dose injectable forms were considered 
for the purposes of medication adherence calculations. 
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6) Medication adherence was calculated per drug class and not for specific drugs. As long 
as a health plan member filled any medication within a drug class, the health plan 
member was considered adherent.  
7) It is assumed that a health plan member is prescribed only one medication per drug 
class.  
 
Portion of Days Covered (PDC) Calculation 
The PDC measures the quantity of days a health plan member has a drug available 
during the study interval by assigning a simple binary measure indicating the presence or 
absence of the study drug for each day in the study period. Therefore, drug oversupplies 
from early refills are not included in PDC calculations. The PDC is a ratio with a range of 
0-1, with a higher number indicating higher adherence. A ratio of greater than 1.0 is not 
possible, as the PDC is capped at 1.0 (Martin et al., 2009).  
PDC = Total Days Medication is Available x 100 
 Total Number of Days Evaluated 
The numerator in the PDC was calculated by utilizing claims data to determine if 
a health plan member had medication coverage for each day in the study period. Dummy 
variables with values of 0 or 1 were assigned to each day in the period. If a health plan 
member had prescription drug coverage for a particular day they were assigned a value of 
1. If they did not have prescription drug coverage for a particular day they were assigned 
a value of 0. The sum of all days that a health plan member had medication coverage 
provided the numerator for the PDC calculation. This approach is common when 
measuring PDC for a therapeutic class, where health plan members are concurrently 
prescribed more than one medication from within the same therapeutic class. It is also 
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useful to account for drug switches, addition of drugs within a class and early refills. 
Counting medications per day prevents over-estimation of adherence values. 
 
Propensity Score Matching 
Propensity score matching (PSM), first published by Paul Rosenbaum and Donald 
Rubin in 1983, is a statistical matching technique that attempts to estimate the effect of a 
treatment, policy or other intervention by accounting for the covariates that predict 
receiving the treatment (Rosenbaum & Rubin, 1983). PSM involves forming matched 
sets of treated and untreated subjects that share a similar value of the propensity score 
(Austin, 2014). PSM attempts to reduce the bias due to confounding variables that could 
be found in an estimate of the treatment effect obtained from simply comparing outcomes 
among health plan members that received the treatment versus those that did not. 
Matching attempts to mimic randomization by creating a sample of health plan members 
that received the treatment that is comparable on all observed covariates to a sample of 
health plan members that did not receive the treatment.  
Propensity score matching utilized the traditional framework of matching two 
groups to make them comparable but rather than match individually on multiple 
variables, it matches them on a single indicator, the propensity score (Rosenbaum & 
Rubin, 1983). When matching, controls from the low-income subsidy group were 
selected who had similar propensity scores to those in the treatment group (those with a 
coverage gap). The goal was a dataset of treatments and controls with similar 
characteristics on all key variables that were used to define the propensity scores. The 
propensity score is defined as the probability of being in the treatment group given the 
40	  
individual's level on the covariates included in the model (Rosenbaum & Rubin, 1983). 
The propensity score was estimated using a logistic regression model. Logistic regression 
makes no assumptions about the distributions of the covariates on the dichotomous 
outcome (D'Agostino 1998). A single propensity score was estimated for every individual 
in the study, both treatments and controls. This propensity score was then used to adjust 
for the differences between the two groups on the observed covariates in the study. Thus, 
the propensity score allows researchers to control for a large number of background 
covariates simultaneously based on a single number (Rosenbaum & Rubin, 1983). 
Based on Andersen's Behavioral Model of Health Services Use as described in 
depth in chapter 2 and a review of the literature citing factors affecting medication 
adherence, the following variables were used as covariates: age, gender and race 
(Andersen, 1995; Zhang et al., 2013). Data on age, gender and race were readily available 
from the data set. 
A random id variable was introduced to allow a different ordering of data for the 
match in order to approximate a randomized control trial. The matching method used was 
the Nearest Neighbor Without Replacement Caliper Match. “Nearest Neighbor” signifies 
treatments are being assigned to controls based on the first pairing that meets the 
matching criteria. “Without Replacement” denotes controls are removed once matched to 
a case so the controls cannot be matched to more than one case. “Caliper” refers to the 
number of decimals used in matching and acts as a constraint to allow the matching 
algorithm to be more or less restrictive. Medical literature recommends that, in most 
situations, nearest neighbor caliper matching without replacement (random order or 
closest distance) be used when forming pairs of treated and untreated subjects with 
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similar values of the propensity score (Austin, 2014). This approach tended to result in 
estimates with minimal bias compared with other algorithms across a wide range of 
scenarios.  
 
Data analyses required to address objectives: 
1) To evaluate diabetes medication adherence of health plan members before they reach 
the coverage gap and then while they are in the coverage gap. 
Data: Pharmacy claims data for Medicare health plan members with no 
prescription drug coverage during the coverage gap. 
Analysis: Statistical significance was assessed at α = 0.05 using a paired t-test to 
compare the pre-coverage and coverage gap mean PDC 
Table 5. Proposed data layout to evaluate Objective 1 






2009    
2010    
2011    
2012    
2013    
2014    
 
2) To compare diabetes medication adherence between two similar groups with differing 
benefit structures, one group with a gap in coverage as opposed to a group with no 
benefit changes within the year. 
Data: Pharmacy claims data for Medicare health plan members enrolled in plans 
with no gap in coverage and Medicare health plan members without any prescription 
drug coverage during the coverage gap. 
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Analysis: Statistical significance was assessed at α = 0.05 using a paired t-test to 
compare the control and treatment mean PDC by year. 
 
Table 6. Proposed data layout to evaluate Objective 2 






2009    
2010    
2011    
2012    
2013    
2014    
 
3) To examine diabetes medication adherence trend over multiple years as the coverage 
gap is closed. 
Data: Pharmacy claims data for Medicare health plan members enrolled in plans 
with no gap in coverage and Medicare health plan members without any prescription 
drug coverage during the coverage gap. 
Analysis: Statistical significance was assessed at α = 0.05 using a paired t-test to 
compare 2009 mean PDC to each subsequent year for both control and treatment groups. 
 
Table 7. Proposed data layout to evaluate Objective 3 







2009 vs 2010   
2009 vs 2011   
2009 vs 2012   
2009 vs 2013   




The University of Louisville Institutional Review Board (IRB) evaluated and 
granted approval for this study after an expedited review. A copy of the approval letter is 
included in Appendix A.  
 
Summary 
This study focuses on Medicare health plan members utilizing diabetic 
medications from a mail order pharmacy. A retrospective, pre-post cohort analysis with 
control group study design was used to determine the effect of the Medicare Part D 
coverage gap on diabetic medication adherence. Medicare health plan members who met 
the study inclusion criteria were selected from the health plan’s covered 7 million lives. 
For members in the study group, total costs and TrOOP were calculated to determine 
whether they entered the coverage gap. Members of the comparison group had no gap in 
coverage during the respective plan year.  
Pre-coverage gap and within coverage gap analysis was conducted for the study 
group. Medication adherence was calculated using PDC, which is the method endorsed 
by the PQA and used by CMS to assign health plan star ratings. Propensity score 
matching was used to obtain balanced control and treatment groups based on covariates 
of age, race and gender. The PSM models were analyzed for goodness of fit. Mean 
adherence was analyzed between the groups along with the mean medication adherence 
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trend over multiple years as the coverage gap is closed due to the ACA. The results 
obtained from the data analyses are presented in Chapter 4.
	   45	  
CHAPTER 4 
RESULTS 	  
This chapter begins with a discussion of the study population and specifics 
regarding the inclusion/exclusion process. Next, details of those reaching the coverage 
gap are presented. In the following section, results of the descriptive analyses of pre-
coverage gap and within coverage gap diabetic medication adherence are provided. Then, 
propensity score matching models are delivered and goodness of fit test results presented. 
Finally, diabetic medication adherence results from the propensity score matched groups 
are offered and compared. 
 
Study Population 
The study sample was selected from Humana Medicare health plan members 
enrolled in a Medicare Advantage (MAPD) prescription drug plan or Part D plan (PDP) 
during the study years of interest. The health plan members were divided into two cohorts 
by brand or generic diabetic medication utilization. Generic formulations of the study 
drugs were identified using a generic product indicator (GPI) variable for each drug in 
each year of the database. 
The following criteria were utilized to determine inclusion/exclusion of the 
treatment group: 
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1) At least one prescription claim for a medication of interest at Humana’s mail 
order pharmacy during the month of January in plan years 2009, 2010, 2011, 
2012, 2013 or 2014 
2) Aged 18 to 89 years at the beginning of the plan year 
3) Exclusion of members eligible for Low Income Subsidy (LIS) benefit (these 
members were utilized for the control group if they met eligibility criteria in the 
next step) 
4) 12 months continuous enrollment in a plan year 
5)  Reached the Medicare coverage gap spending limits between April 1st and 
September 30th during the respective plan year 
Figure 6 presents the study sample and health plan members using brand diabetic 
medications that reached the coverage gap. Figure 7 presents the study sample and health 
plan members using generic diabetic medications that reached the coverage gap. There is 
a significant decrease in study population during the last step because a relatively small 











Of the health plan members who met the study inclusion and exclusion criteria, a 
greater percentage of brand diabetic medication utilizers entered the coverage gap as 
compared with those utilizing generic medication. As shown in Figure 8, the percentage 
of health plan members reaching the coverage gap increased steadily each year for the 
brand cohort. The generic cohort exhibited a slight increase year over year with the 
exception of years 2012-2013. 
 




Coverage gap month 
The percent of health plan members who entered the coverage gap between April 
and September, by cohort are shown in Figures 9 and 10. Of those members who entered 
the coverage gap in this study, the largest percentage moved into the coverage gap in 
September, regardless of cohort. 
2009$ 2010$ 2011$ 2012$ 2013$ 2014$
Brand$ 4.62%$ 5.81%$ 12.24%$ 13.12%$ 17.89%$ 24.01%$










Figure 9. Percent of health plan members utilizing brand diabetic medications who reach 




Figure 10. Percent of health plan members utilizing generic diabetic medications who 




April& May& June& July& Aug& Sept&
2009& 1.54%& 7.31%& 13.46%& 23.85%& 24.62%& 29.23%&
2010& 2.33%& 7.49%& 12.40%& 21.71%& 21.96%& 34.11%&
2011& 2.97%& 5.62%& 11.98%& 16.44%& 21.95%& 41.04%&
2012& 6.00%& 9.13%& 9.59%& 19.37%& 24.91%& 31.00%&
2013& 3.13%& 3.65%& 8.43%& 14.87%& 27.30%& 42.61%&











April& May& June& July& Aug& Sept&
2009& 1.18%& 7.06%& 12.35%& 18.24%& 28.82%& 32.35%&
2010& 1.07%& 6.41%& 11.74%& 21.71%& 21.71%& 37.37%&
2011& 2.36%& 5.32%& 10.49%& 16.99%& 21.71%& 43.13%&
2012& 6.77%& 10.26%& 10.59%& 19.21%& 23.80%& 29.37%&
2013& 4.39%& 5.46%& 9.16%& 17.74%& 26.90%& 36.35%&













It is possible for health plan members to fall into both cohorts if they are using 
both brand and generic medications. A breakout of these groups is provided in Table 8. 
The percentage of health plan members using only generic medications increased while 
the groups using only brand medications and both medications declined over the study 
period. 
Table 8. Percent of total health plan members utilizing brand only, generic only or both 
 2009 2010 2011 2012 2013 2014 
Brand only 41% 34% 35% 33% 35% 36% 
















Figures 11-13 present the percent of health plan members who hit the gap by month 
based on whether they used brand, generic or both medications. 
 
Figure 11. Percent of health plan members utilizing only brand diabetic medications who 









Figure 12. Percent of health plan members utilizing only generic diabetic medications 




Figure 13. Percent of health plan members utilizing both brand and generic diabetic 
medications who reach the coverage gap between April and September, by month 
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Descriptive analyses of pre-coverage gap and within coverage gap medication 
adherence 
Mean medication adherence by cohort for health plan members before they 
reached the coverage gap and then while they were in the coverage gap is displayed in 
Tables 9 and 10. As shown in the tables, overall pre-coverage gap medication adherence 
was higher than medication adherence while in the coverage gap. Paired t-tests indicate 
significant differences in the brand cohort for all years and the generic cohort for years 
2010-2012. 
 
Table 9. Univariate analysis comparing medication adherence pre-coverage gap and 
within the coverage gap for the brand cohort  






Paired T test 
 N Mean SD Mean SD Mean SD DF t p 
2009 260 0.901  0.097 0.861 0.184 0.040 0.207 259 3.15 0.0018 
2010 387 0.909 0.080 0.868 0.168 0.041 0.185 296 4.33 <0.0001 
2011 943 0.909 0.078 0.857 0.159 0.051 0.178 942 8.84 <0.0001 
2012 1084 0.883 0.100 0.828 0.197 0.055 0.218 1083 8.32 <0.0001 
2013 1150 0.877 0.101 0.835 0.190 0.042 0.206 1149 6.96 <0.0001 
2014 2002 0.858 0.116 0.828 0.195 0.030 0.216 2001 6.30 <0.0001 
 
Table 10. Univariate analysis comparing medication adherence pre-coverage gap and 
within the coverage gap for the generic cohort  






Paired T test 
 N Mean SD Mean SD Mean SD DF t p 
2009 170 0.870 0.111 0.845 0.211 0.025 0.194 169 1.68 0.0940 
2010 281 0.883 0.127 0.822 0.237 0.061 0.225 280 4.52 <0.0001 
2011 677 0.882 0.119 0.847 0.211 0.035 0.209 676 4.30 <0.0001 
2012 916 0.873 0.117 0.829 0.231 0.043 0.236 915 5.55 <0.0001 
2013 1026 0.874 0.125 0.865 0.223 0.009 0.210 1025 1.38 0.1671 
2014 1727 0.876 0.118 0.867 0.222 0.009 0.215 1726 1.74 0.0823 
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As previously noted, PQA selected 0.8 (or 80 percent) as the threshold above 
which the patient can be considered to be adherent for most classes of chronic 
medications. The percent of health plan members in each cohort that were adherent with 
a PDC > 80% during the pre-coverage gap phase and during the coverage gap phase are 
presented in Figures 14 and 15. In each cohort, the percentage of adherent members was 
greater in the pre-coverage gap period versus the gap period (consistent p-value < 0.05). 
The health plan member cost share amount for the index fill in January, as well as 
the days spent pre-gap and within the coverage gap are presented in Tables 11 and 12. In 
general, the findings reflect an increase in member cost share for brand diabetic 
medications year over year.  
 
Figure 14. Percent of health plan members utilizing brand diabetic medications that were 










2009$ 2010$ 2011$ 2012$ 2013$ 2014$
Pre+Cov.$Gap$ 88.10%$ 93.00%$ 91.50%$ 84.00%$ 82.80%$ 75.30%$















Figure 15. Percent of health plan members utilizing generic diabetic medications that 




Table 11. Index fill cost share, days spent in pre-coverage gap and coverage gap for 
health plan members using brand diabetic medications   
 2009 2010 2011 2012 2013 2014 





40.36 42.73 45.96 49.38 49.10 58.80 
Days Pre-Gap 211.7 214.4 219.2 210.5 224.9 213.8 
Days Gap 153.3 150.6 145.8 155.5 140.1 151.2 
All numbers reported as mean 
 
 
Table 12. Index fill cost share, days spent in pre-coverage gap and coverage gap for 
health plan members using generic diabetic medications   
 2009 2010 2011 2012 2013 2014 





4.25 1.53 1.90 1.79 9.65 4.76 
Days Pre-Gap 216.7 217.8 222.0 207.4 218.1 214.3 
Days Gap 148.3 147.2 143.0 158.6 146.8 150.7 
All numbers reported as mean 
2009$ 2010$ 2011$ 2012$ 2013$ 2014$
Pre+Cov.$Gap$ 80.60%$ 84.30%$ 83.90%$ 81.40%$ 82.60%$ 82.30%$













Propensity score matching 
Objective 2 required the used of a control group. Medicare Part D health plan 
members eligible for a low-income subsidy (LIS) were chosen because they do not incur 
the full cost of medications in the Part D coverage gap. The following criteria were 
utilized to determine inclusion/exclusion of the control group: 
1) At least one prescription claim for a medication of interest at Humana’s mail 
order pharmacy during the month of January in plan years 2009, 2010, 2011, 
2012, 2013 or 2014 
2) Aged 18 to 89 years at the beginning of the plan year 
3) 12 months continuous enrollment in a plan year 
4)  Reached the Medicare coverage gap spending limits between April 1st and 
September 30th during the respective plan year 
The propensity score for matching was obtained utilizing a logistic regression 
analysis where the dependent variable was a LIS indicator. Excluded from the matched 
sample were untreated subjects that could not be matched to a treated subject with a 
propensity score within the caliper range of 0.001. The caliper refers to the number of 
decimals allowed for a treatment to be matched to a control based on propensity score. 
Smaller calipers result in stricter matches. A “greedy”, nearest-neighbor matching 
algorithm was utilized to form pairs of treated and untreated subjects. Austin advises 
“greedy, nearest neighbor matching within specified caliper widths may not result in all 
treated subjects being matched to an untreated subject, because for some treated subjects, 
there may not be any untreated subjects who are unmatched and whose propensity score 
lies within the specified caliper distance of that of the treated subject (Austin, 2014).” 
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Prior to analyzing any results from a propensity- score matched model, it is 
necessary to evaluate the model’s goodness of fit. Ho et al. suggest the propensity-score 
model is adequate when the distribution of measured baseline covariates is similar 
between treated and untreated subjects (D. Ho, Imai, King, & Stuart, 2007). Therefore, 
the appropriateness of the model is assessed by examining the degree to which matching 
on the estimated propensity score has resulted in a matched sample where the distribution 
of measured baseline covariates is similar between treated and untreated subjects (Austin, 
2014). 
The method used to assess the model’s fit in this study was standardized 
difference. The standardized difference compares the difference in means in units of the 
pooled standard deviation (Austin, 2014). The standardized difference is not influenced 
by sample size unlike t-tests and other statistical tests of hypothesis. Therefore, the 
standard difference can be useful to evaluate balance in measured variables between 
treated and untreated subjects in the matched sample with that in the unmatched sample. 
Rosenbaum and Rubin first published their use of the standardized difference to assess 
the comparability of treated and untreated subjects in matched samples (Rosenbaum & 
Rubin, 1985). Since then, several authors have used this approach in the clinical literature 
(Austin, 2008a, 2008c; Normand et al., 2001)  
Absolute standardized differences comparing baseline covariates between treated 
and untreated subjects in the unmatched and matched samples are reported in Tables 13 - 
24. In the unmatched sample, the largest absolute standardized differences were observed 
in the age difference of the groups with the control group being younger than the 
treatment group (0.200 – 0.759). In general, the propensity score resulted in a matched 
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sample in which the means and percentages of baseline covariates were relatively similar 
between treated and untreated subjects. For example, the ability of PSM to equalize 
variables is illustrated in Table 13. The unmatched control group had a mean age of 64.7 
years, a little over half were female and less than a third of the members were white. The 
matched sample equalized the variability so both samples were 69.1 years in mean age, a 
little over half were female and race exhibited a far less pronounced gap. While PSM 
attempts to reduce the difference among the groups, it cannot eliminate them completely. 
For example, as shown in Table 19, some marked differences remain in the matched 
groups for mean age (69.7 vs. 72.0) and gender (53.5% vs. 77.0%). 
 
Table 13. Comparison of baseline statistics for unmatched and matched health plan 
members for brand diabetic medication cohort, 2009  
 Original Unmatched Sample Propensity-score Matched Sample 
Var. Control 
LI: Yes  
(N = 45)  
Treatment 
LI: No  




LI: Yes  
(N = 27)  
Treatment 
LI: No  
(N = 27) 
Std.	  
Diff.	  
Age 64.7 ± 9.8 70.7 ± 6.1 0.726 69.1 ± 6.0 69.1 ± 5.9 0.006 
Female 25 (55.6%) 91 (35.0%) 0.422 16 (59.2%) 16 (59.2%) 0.000 
White 70 (26.9%) 188 (72.3%) 0.027 22 (81.5%) 21 (77.8%) 0.092 
Continuous variables are reported as mean ± standard deviation.  
Dichotomous variables are reported as N (percent). 	  
Table 14. Comparison of baseline statistics for unmatched and matched health plan 
members for generic diabetic medication cohort, 2009  
 Original Unmatched Sample Propensity-score Matched Sample 
Var. Control 
LI: Yes  
(N = 29)  
Treatment 
LI: No  




LI: Yes  
(N = 18)  
Treatment 
LI: No  
(N = 18) 
Std.	  
Diff.	  
Age 65.4 ± 10.3 71.0 ± 5.7 0.681 70.5 ± 5.3 70.6 ± 5.5 0.010 
Female 12 (41.4%) 63 (37.1%) 0.089 9 (50.0%) 9 (50.0%) 0.000 
White 21 (72.4%) 125 (73.5%) 0.035 14 (77.8%) 16 (88.9%) 0.302 
Continuous variables are reported as mean ± standard deviation.  




Table 15. Comparison of baseline statistics for unmatched and matched health plan 
members for brand diabetic medication cohort, 2010  
 Original Unmatched Sample Propensity-score Matched Sample 
Var. Control 
LI: Yes  
(N = 79)  
Treatment 
LI: No  




LI: Yes  
(N = 58)  
Treatment 
LI: No  
(N = 58) 
Std.	  
Diff.	  
Age 68.9 ± 9.7 70.7 ± 5.7 0.238 70.6 ± 7.9 71.1 ± 5.8 0.074 
Female 47 (59.5%) 145 (37.5%) 0.452 33 (56.9%) 33 (56.9%) 0.000 
White 55 (69.6%) 312 (80.6%) 0.257 45 (75.6%) 42 (72.4%) 0.120 
Continuous variables are reported as mean ± standard deviation.  
Dichotomous variables are reported as N (percent). 
 
 
Table 16. Comparison of baseline statistics for unmatched and matched health plan 
members for generic diabetic medication cohort, 2010  
 Original Unmatched Sample Propensity-score Matched Sample 
Var. Control 
LI: Yes  
(N = 53)  
Treatment 
LI: No  




LI: Yes  
(N = 39)  
Treatment 
LI: No  
(N = 39) 
Std.	  
Diff.	  
Age 69.2 ± 7.9 70.5 ± 5.4 0.200 70.9 ± 5.3 70.7 ± 5.4 0.043 
Female 35 (66.0%) 105 (37.3%) 0.599 24 (30.8%) 24 (30.8%) 0.000 
White 41 (77.4%) 226 (80.4%) 0.075 31 (79.5%) 32 (82.1%) 0.065 
Continuous variables are reported as mean ± standard deviation.  
Dichotomous variables are reported as N (percent). 
 
Table 17. Comparison of baseline statistics for unmatched and matched health plan 
members for brand diabetic medication cohort, 2011  
 Original Unmatched Sample Propensity-score Matched Sample 
Var. Control 
LI: Yes  
(N = 136)  
Treatment 
LI: No  




LI: Yes  
(N = 101)  
Treatment 
LI: No  
(N = 101) 
Std.	  
Diff.	  
Age 66.8 ± 9.4 71.0 ± 5.9 0.540 69.4 ± 7.4 69.7 ± 7.8 0.040 
Female 81 (59.6%) 344 (36.5%) 0.475 61 (60.4%) 65 (64.4%) 0.082 
White 103 (75.7%) 844 (89.5%) 0.369 85 (84.2%) 85 (84.2%) 0.000 
Continuous variables are reported as mean ± standard deviation.  
Dichotomous variables are reported as N (percent). 	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Table 18. Comparison of baseline statistics for unmatched and matched health plan 
members for generic diabetic medication cohort, 2011  
 Original Unmatched Sample Propensity-score Matched Sample 
Var. Control 
LI: Yes  
(N = 111)  
Treatment 
LI: No  




LI: Yes  
(N = 81)  
Treatment 
LI: No  
(N = 81) 
Std.	  
Diff.	  
Age 66.2 ± 9.9 70.8 ± 5.8 0.565 69.3 ± 7.5 70.7 ± 7.0 0.186 
Female 64 (57.7%) 258 (38.1%) 0.399 46 (56.8%) 56 (69.1%) 0.258 
White 86 (77.5%) 603 (89.1%) 0.314 70 (86.4%) 60 (74.1%) 0.314 
Continuous variables are reported as mean ± standard deviation.  
Dichotomous variables are reported as N (percent). 
 
 
Table 19. Comparison of baseline statistics for unmatched and matched health plan 
members for brand diabetic medication cohort, 2012 
 Original Unmatched Sample Propensity-score Matched Sample 
Var. Control 
LI: Yes  
(N = 344)  
Treatment 
LI: No  




LI: Yes  
(N = 217)  
Treatment 
LI: No  
(N = 217) 
Std.	  
Diff.	  
Age 65.1 ± 10.3 71.1 ± 5.8 0.717 69.7 ± 7.2 72.0 ± 7.9 0.307 
Female 202 (58.7%) 360 (33.2%) 0.530 116 (53.5%) 167 (77.0%) 0.509 
White 274 (79.7%) 1016 (93.7%) 0.424 198 (91.2%) 200 (92.2%) 0.033 
Continuous variables are reported as mean ± standard deviation.  
Dichotomous variables are reported as N (percent). 	  
Table 20. Comparison of baseline statistics for unmatched and matched health plan 
members for generic diabetic medication cohort, 2012 
 Original Unmatched Sample Propensity-score Matched Sample 
Var. Control 
LI: Yes  
(N = 291)  
Treatment 
LI: No  




LI: Yes  
(N = 196)  
Treatment 
LI: No  
(N = 196) 
Std.	  
Diff.	  
Age 64.9 ± 10.3 70.6 ± 5.7 0.680 68.6 ± 7.5 68.6 ± 7.3 0.002 
Female 176 (60.5%) 314 (34.3%) 0.544 115 (58.7%) 114 (58.2%) 0.010 
White 228 (74.4%) 846 (92.4%) 0.404 175 (89.3%) 174 (88.8%) 0.016 
Continuous variables are reported as mean ± standard deviation.  






Table 21. Comparison of baseline statistics for unmatched and matched health plan 
members for brand diabetic medication cohort, 2013 
 Original Unmatched Sample Propensity-score Matched Sample 
Var. Control 
LI: Yes  
(N = 392)  
Treatment 
LI: No  




LI: Yes  
(N = 275)  
Treatment 
LI: No  
(N = 275) 
Std.	  
Diff.	  
Age 69.2 ± 10.6 71.2 ± 5.8 0.702 68.8 ± 8.3 71.7 ± 6.6 0.385 
Female 269 (68.6%) 469 (40.8%) 0.583 169 (61.5%) 241 (87.6%) 0.630 
White 317 (80.9%) 1064 (92.5%) 0.348 244 (88.7%) 243 (88.4%) 0.011 
Continuous variables are reported as mean ± standard deviation.  
Dichotomous variables are reported as N (percent). 	  
Table 22. Comparison of baseline statistics for unmatched and matched health plan 
members for generic diabetic medication cohort, 2013 
 Original Unmatched Sample Propensity-score Matched Sample 
Var. Control 
LI: Yes  
(N = 357)  
Treatment 
LI: No  




LI: Yes  
(N = 221)  
Treatment 
LI: No  
(N = 221) 
Std.	  
Diff.	  
Age 64.6 ± 10.2 70.5 ± 5.8 0.712 69.1 ± 6.8 69.3 ± 7.1 0.029 
Female 248 (69.5%) 416 (40.6%) 0.608 151 (68.3%) 154 (70.1%) 0.039 
White 284 (79.6%) 939 (91.5%) 0.345 200 (90.5%) 200 (90.5%) 0.000 
Continuous variables are reported as mean ± standard deviation.  
Dichotomous variables are reported as N (percent). 
 
Table 23. Comparison of baseline statistics for unmatched and matched health plan 
members for brand diabetic medication cohort, 2014 
 Original Unmatched Sample Propensity-score Matched Sample 
Var. Control 
LI: Yes  
(N = 665)  
Treatment 
LI: No  




LI: Yes  
(N = 460)  
Treatment 
LI: No  
(N = 460) 
Std.	  
Diff.	  
Age 65.2 ± 10.3 71.2 ± 6.2 0.701 69.4 ± 7.3 69.5 ± 7.6 0.019 
Female 431 (64.8%) 839 (41.9%) 0.472 293 (63.7%) 307 (66.7%) 0.064 
White 505 (75.9%) 1836 (91.7%) 0.438 380 (82.6%) 378 (82.2%) 0.011 
Continuous variables are reported as mean ± standard deviation.  
Dichotomous variables are reported as N (percent). 	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Table 24. Comparison of baseline statistics for unmatched and matched health plan 
members for generic diabetic medication cohort, 2014 
 Original Unmatched Sample Propensity-score Matched Sample 
Var. Control 
LI: Yes  
(N = 589)  
Treatment 
LI: No  




LI: Yes  
(N = 408)  
Treatment 
LI: No  
(N = 408) 
Std.	  
Diff.	  
Age 64.6 ± 10.1 70.9 ±6.1 0.759 68.3 ± 7.5 68.5 ± 7.5 0.029 
Female 380 (64.5%) 718 (41.6%) 0.472 264 (64.7%) 270 (66.2%) 0.030 
White 458 (77.8%) 1587 (91.9%) 0.402 348 (85.3%) 340 (83.3%) 0.054 
Continuous variables are reported as mean ± standard deviation.  
Dichotomous variables are reported as N (percent). 
 
The C-statistic, which is an indicator for concordance, is also useful in evaluating 
the goodness of fit of logistic regression models. The C-Statistic offers values ranging 
from 0.5 to 1.0. A value of 0.5 indicates that the model is no better than chance at making 
a prediction of membership in a group and a value of 1.0 indicates that the model 
perfectly identifies those within a group and those not. Models are typically considered 
reasonable when the C-statistic is higher than 0.7 and strong when C exceeds 0.8 
(Hosmer & Lemeshow, 1989). All C-statistics were above 0.7 and are provided in Table 
25. 
 
Table 25. C-statistics for logistic regression models by year, medication cohort 




2009 0.773 0.700 
2010 0.701 0.706 
2011 0.713 0.705 
2012 0.761 0.759 
2013 0.761 0.761 
2014 0.755 0.765 
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Descriptive analyses of propensity score matched control and treatment groups 
Mean medication adherence by cohort for propensity score matched health plan 
members is presented in Tables 26 - 27. The control group represents those health plan 
members with no gap in coverage during the plan year and the treatment group represents 
those health plan members who reached the Part D coverage gap. As shown in the tables, 
the control group exhibited higher medication adherence. T-tests indicate significant 
differences in the brand cohort for years 2011-2014 and the generic cohort for years 
2013-2014. 
 
Table 26. Univariate analysis comparing medication adherence of the control and 
treatment groups for the brand cohort  
Brand Control 
Group 





 N Mean SD Mean SD Mean SD DF t p 
2009 27 0.928 0.070 0.884 0.104 0.044 0.089 52 1.83 0.0730 
2010 58 0.927 0.093 0.901 0.082 0.026 0.088 114 1.62 0.1091 
2011 101 0.919 0.090 0.879 0.095 0.041 0.013 200 3.12 0.0021 
2012 217 0.919 0.082 0.874 0.115 0.046 0.100 432 4.74 <0.0001 
2013 275 0.910 0.093 0.857 0.111 0.053 0.102 548 6.12 <0.0001 
2014 460 0.913 0.087 0.839 0.121 0.074 0.106 918 10.65 <0.0001 
 
Table 27. Univariate analysis comparing medication adherence of the control and 
treatment groups for the generic cohort 
Generic Control 
Group 





 N Mean SD Mean SD Mean SD DF t p 
2009 18 0.899 0.121 0.899 0.084 0.000 0.106 30 0.01 0.9928 
2010 39 0.882 0.170 0.849 0.181 0.034 0.175 76 0.85 0.4000 
2011 81 0.876 0.165 0.883 0.108 0.007 0.140 138 0.34 0.7368 
2012 196 0.889 0.146 0.867 0.140 0.022 0.143 390 1.51 0.1318 
2013 221 0.899 0.138 0.871 0.135 0.028 0.137 435 2.16 0.0311 
2014 408 0.903 0.136 0.874 0.127 0.029 0.132 808 3.17 0.0016 
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Diabetic medication adherence across plan years  
Medication adherence across plan years is presented in Figures 16-19. Plan year 
2009 is used as a reference and statistical significance is denoted with an asterisk. The 
only statistically significant difference was seen in the decline in brand diabetic 
medication adherence for the treatment group from 2009 to 2014 
 

















Figure 17. Control group medication adherence across plan years for the generic cohort 
 
Figure 18. Treatment group medication adherence across plan years for the brand cohort 
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The percent of eligible study participants who reached the coverage gap more 
than doubled between 2009 and 2014. Overall pre-coverage gap medication adherence 
was higher than medication adherence in the coverage gap. Significant differences were 
noted in the brand cohort for all years and the generic cohort for years 2010-2012. A 
comparison of medication adherence between the control and treatment group showed 
statistically significant differences for almost all years in the brand cohort and later year s 
in the generic cohort. However, medication adherence across plan years showed 
statistically significant differences for one year in the treatment brand cohort only. 




This chapter begins with a discussion of the study results with regard to the 
research objectives. In addition to the results, a discussion of strengths, limitations, 
findings and recommendations for future research are offered.  
 
Coverage Gap 
As shown in Figure 8, the percent of eligible study participants in the brand 
cohort who entered the coverage gap ranged from 4.62 percent (2009) to 24.01 percent 
(2014). In the generic cohort, the percent of eligible study participants who entered the 
coverage gap ranged from 0.82 percent (2009) to 1.98 percent (2014). A study conducted 
by Kaiser Family Foundation reported that 26 percent of non-LIS Part D enrollees who 
filled one or more prescriptions in 2007 reached the coverage gap (Hoadley, Hargrave, 
Cubanski, & Neuman, 2008). Each year the Medicare Payment Commission (MEDPAC) 
publishes the percent of Part D enrollees that reach the coverage gap in The Medicare 
Payment Policy Report to the Congress. Data available for non-LIS Part D enrollees from 
2009 through 2012 is displayed in Figure 20. Since 2007, the proportion of Part D non-
LIS enrollees reaching the gap has declined, likely due to the increased availability of 
generic medications for many chronic conditions (Hoadley et al., 2011). However, the 
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absolute number of people reaching the gap has declined less than the proportion because 
of an increase in the number of Part D enrollees as shown in Table 28. 
 
Figure 20. Percent of non-LIS Part D enrollees who entered the coverage gap, 2009-2012 
(Medicare Payment Advisory Commission, 2012, 2013, 2014, 2015) 
 
 
Table 28. Medicare Part D Plan Enrollment Trends, 2007 – 2014 (Medicare Payment 































Total Part D enrollment 
(in millions) 24.2 25.6 27.6 31.5 37.4 6% 
  Percent of Medicare  
  enrollees 54% 56% 58% 60% 69%  
LIS (in millions) 9.4 9.6 9.9 10.8 11.4 3% 
Non-LIS (in millions) 14.8 16.0 17.1 10.7 26.0 8% 
  Percent receiving the  




















The percent of health plan members who reached the gap in this study fell within 
a broad range, likely due to the strict limitations for inclusion (i.e., fill in January, fill at 
mail order, diabetic medications only). In this study, the increase in the percentage of 
health plan members reaching the gap year over year may be due in part to the rising cost 
and increased availability of branded medications in the diabetic class. During the study 
period, there were a total of six branded medications that lost their patent and had generic 
medications launch, which increases competition and drives down the medication price. 
However, there were thirteen FDA approvals and brand medications that launched during 
this period. Brand medications are expensive and could increase spending to move people 
into the coverage gap. Figure 21 shows the movement of brand medications and patent 
losses in the market over the study period along with the percent of health plan members 
who reached the gap. 
 




The 2014 Drug Trend Report produced by The Express Scripts Lab stated that the 
diabetes medication category experienced a higher per-member-per-year (PMPY) spend 
($358.93) than any other traditional therapy class among Medicare enrollees (The 
Express Scripts Lab, 2015). This represented a 26.4% increase in trend over 2013, mainly 
due to unit cost (21.5%). While popular branded drugs like nateglinide (brand name 
Starlix), pioglitazone (brand name Actos), pioglitazone hydrochloride/metformin 
hydrochloride (brand name Actosplus MET), glimepiride/pioglitazone (brand name 
Duetact), rosiglitazone (brand name Avandia) and repaglinide (brand name Prandin) lost 
patent and became available in a generic form during the study period, they were 
replaced by new branded medications. Table 29 contains the specific diabetic 
medications approved by the U.S. Food and Drug Administration during the study period. 
 
Table 29. Insulin and diabetic medications approved between 2009 – 2014 (U.S. Food 
and Drug Administration, 2015) 
Drug Class Brand Name Generic Name Approval Date 
DPP-4 Onglyza saxagliptin July 2009 
GLP-1 Victoza liraglutide January 2010 
DPP-4 Kombiglyze XR saxagliptin/metformin  November 2010 
DPP-4 Tradjenta linagliptin May 2011 
DPP-4 Juvisync sitagliptin/simvistatin October 2011 
GLP-1 Bydureon exenatide synthetic January 2012 
DPP-4 Jentadueto linagliptin/metformin February 2012 
DPP-4 Janumet XR sitagliptin/metformin February 2012 
SGLT-2 Farxiga dapagliflozin January 2014 




insulin human June 2014 
SGLT-2 Jardiance empagliflozin August 2014 
GLP-1 Trulicity duglaglutide September 2014 
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In addition to the market entry of new branded products, highly utilized 
medications saw double-digit increases in unit-cost trend, including insulin glargine 
[rDNA origin] (brand name Lantus) and sitagliptin (brand name Januvia) (The Express 
Scripts Lab, 2015). Although insulin was excluded from adherence calculations in this 
study, the cost did contribute to a member reaching the coverage gap. As presented in 
Table 11, the average member cost of the brand diabetic medication index fill increased 
from $40.38 in 2009 to $58.80 in 2014. 
The graph in Figure 22 depicts the prescription price index of brand and generic 
medications utilizing 2008 dollars as a baseline. As stated in the 2014 Drug Trend 
Report, “from the base price of $100.00 set in January 2008, in December 2014 prices for 
the most commonly used generic medications decreased to $37.13 (in 2008 dollars) and 
prices for the most commonly used brand medications increased to $227.39 (in 2008 
dollars). In contrast, a market basket of commonly used household goods costing $100.00 
in 2008, as measured by the Bureau of Labor Statistics (BLS) Consumer Price Index, 















Pre-coverage gap and within coverage gap medication adherence 
The first objective of the study was to evaluate diabetes medication adherence of 
health plan members before they reach the coverage gap and then while they are in the 
coverage gap. The study participants were separated into two cohorts by brand and 
generic medication utilization. The results of this study indicate that health plan members 
using brand medications decreased medication adherence once they entered the coverage 
gap for all years. The brand cohort also had a decrease in medication adherence year over 
year both before the health plan members entered the coverage gap and while in the 
coverage gap as presented in Figure 23. As shown in Table 9, the difference in the mean 
between the pre-gap adherence and within-gap adherence decreased from 2009 (0.040) to 
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2014 (0.030). In other words, although adherence was decreasing once health plan 
members entered the gap, the decline was less in 2014. 




In the generic cohort, there was observed a decline in medication adherence once 
health plan members entered the coverage gap. Medication adherence prior to entering 
the coverage gap remained relatively flat year over year while adherence in the coverage 
gap fluctuated as shown in Figure 24. They also exhibited a decrease in the difference in 
the mean between the pre-gap adherence and within-gap adherence over the study period. 
































These findings are consistent with other published studies. A decrease in 
adherence to medications in the coverage gap was reported in studies conducted by Gu, et 
al., Li, et al., Sacks, et al. and Zhang, et al (Gu, Zeng, Patel, & Tripoli, 2010; Li et al., 
2012; Sacks et al., 2013; Zhang et al., 2013). Researchers in Zhang’s study also found 
that health plan members with generic coverage in the coverage gap decreased brand 
utilization significantly and generic utilization slightly, even though generic medications 
were covered under their prescription drug benefit. The Kaiser Family Foundation 
published a study finding that among Part D health plan members using medications for 
diabetes who reached the coverage gap in 2007, 10 percent stopped taking their diabetes 





















Demographics for propensity score matched groups 
 
 The second objective was to compare diabetes medication adherence between two 
similar groups with differing benefit structures, one group with a gap in coverage as 
opposed to a group with no benefit changes within the year. Health plan members eligible 
for a low-income subsidy (LIS) were used as the control group. Health plan members 
with no benefit once reaching the coverage gap were used as the treatment group. The 
unmatched groups exhibited a great degree of variation. As a result, propensity score 
matching was conducted using age, race and sex as covariates. Both groups filled a 
diabetic medication at Humana’s mail order pharmacy in January of the respective plan 
year. In addition, both groups had total drug costs that would qualify them to reach the 
Medicare Part D coverage gap in the respective plan years albeit the control group did not 
incur the actual costs associated with reaching the coverage gap. The control and 
treatment groups were equalized but some variability remained across years. Treatment 
group demographics across plan years are displayed in Tables 30-31. 
 
Table 30. Demographics across plan years for treatment group using brand medications 
 2009 2010 2011 2012 2013 2014 
Age 
(mean) 
69.1 71.1 69.1 72.0 71.7 69.5 
Female  59.3% 56.9% 64.4% 77.0% 87.6% 66.7% 
White 77.8% 72.4% 84.2% 92.2% 88.4% 82.2% 
 
Table 31. Demographics across plan years for treatment group using generic medications 
 2009 2010 2011 2012 2013 2014 
Age 
(mean) 
70.6 70.7 70.7 68.6 69.3 68.5 
Female  50.0% 61.5% 69.1% 58.2% 70.1% 66.2% 
White 88.9% 82.1% 74.1% 88.8% 90.5% 83.3% 
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Medication adherence in control and treatment groups 	  
In general, the control group exhibited better medication adherence than the 
treatment group as displayed in Figures 25-26. These results align with other published 
studies. Researchers of a cross-sectional, retrospective analysis using claims from 2005-
2006 showed LIS health plan members had better diabetic medication adherence (62.5%) 
than non-LIS health plan members with no coverage gap benefit (57.7%) (Yala et al., 
2014). In a retrospective cohort study using data from the U.S. Renal Data System 
(USRDS), researchers examined medication adherence for Medicare-eligible dialysis 
patients (Park et al., 2014). The health plan members were separated into four groups: 
Cohort 1 consisted of those that did not reach the coverage gap, Cohort 2 entered the 
coverage gap, Cohort 3 had spending to qualify catastrophic coverage and Cohort 4 were 
LIS members. Health plan members in cohort 2 on diabetic medications had a significant 
decrease in medication adherence once they entered the coverage gap (72.4% vs. 57.9%). 
In addition, LIS members had statistically significant better diabetic medication 


















Figure 25. Medication adherence of the control and treatment groups for the brand cohort  
	  
 




Medication adherence across plan years 
The third objective was to examine the diabetes medication adherence trend over 
multiple years as the coverage gap is closed. As Table 3 outlined, the member cost share 
in the coverage gap began to decrease starting in 2010 but at the same time for most years 
the initial deducible, the threshold to enter the coverage gap and the catastrophic phase 
entry threshold all increased. This means health plan members faced the possibility of 
higher out of pocket costs before reaching the coverage gap. 
The adherence for the control group, both brand and generic cohorts contained 
very little fluctuation year over year. Treatment group adherence for brand medications 
increased in year 2010 but then showed a decline each additional year. Treatment group 
adherence for generic medications fluctuated but showed an overall decrease from year 
2009. 
Although multiple studies have been conducted on the effect of the Part D 
coverage gap on medication adherence, few studies exist that examine the effect of 
closing the coverage gap. In a study conducted by Zeng, et al., researchers found 
adherence of health plan members in a national Pharmacy Benefit Manager (PBM) 
increased from 2010 to 2011 as the coverage gap initially began to close (Zeng et al., 
2013). Additionally, in a study conducted by Brown, et al. initial data from another 
national PBM indicated adherence was modestly improving across plan years from 2009 
to 2011 for brand medications (Brown et al., 2012). 
A possible explanation for the finding that adherence is decreasing as the 
coverage gap is closing could be the limitation of the study population to mail order 
utilizers. In a literature search conducted by Cramer on findings from 1966 – 2003, 
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overall oral diabetic medication adherence was found to range from 36 – 93 percent 
(Cramer, 2004). In another literature review conducted by DiMatteo, mean diabetic 
medication adherence from 23 studies was found to be 67.5 percent (DiMatteo, 2004). 
Finally, Express Scripts reports average diabetic therapy adherence at 79.1 percent (2009) 
and 79.2 percent (2010) (The Express Scripts Lab, 2010, 2011). However, studies have 
shown when segregated, mail order utilizers have higher adherence than health plan 
members who fill at retail pharmacies. In 2011, Khandelwal, et al. noted no significant 
adherence difference in 90-day at retail verses mail order utilization except in the diabetic 
medication class (80.2 vs. 83.1 percent) (Khandelwal et al., 2011). Researches using 
diabetic patient data from Kaiser Permanente Northern California reported similar results, 
mail order (84.7 percent) versus retail pharmacy (76.9 percent) (Duru et al., 2010). 
Finally, in 2014 researchers presented data showing a significant difference in diabetic 
medication adherence in mail order  (90.9 percent) versus retail (66.8 percent) (Iyengar & 
Lefrancois, 2014). By limiting the study population to mail order utilizers who already 
exhibit a high medication adherence, the opportunity to identify significant changes in 
adherence may have been hindered.  
However, the study findings indicate a decrease in adherence rather than the 
expected increase associated with reducing the coverage gap cost barrier. Although the 
coverage gap amount was decreasing during the study period, there were additional cost 
pressures from medication price inflation, increases in benefit caps and a downturn in the 
economy. As noted in the 2011 Drug Trend Report, “intensity, changes in adherence to 
medication, has suffered during the recent economic downturn as some patients have 
reacted to financial stress by foregoing their medications or taking them less frequently 
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than prescribed to save money. We anticipate that intensity will increase as the economy 
improves.” (The Express Scripts Lab, 2012) 
Finally, cost is only one determinant of patient adherence. Piette, et al. described 
the cost-adherence relationship as “modified by contextual factors, including patients' 
characteristics (e.g., age, ethnicity, and attitudes toward medications), the type of 
medications they are using (e.g., the complexity of dosing and the drug's clinical target), 
clinician factors (e.g., choice of first-line agent and communication about medication 
costs), and health system factors (e.g., efforts to influence clinicians' prescribing and to 
help patients apply for financial assistance programs) (Piette, Heisler, Horne, & Caleb, 
2006).”  
 
Strengths and Limitations 
Evidence from the literature suggests that health plan members reduce the use of 
medications while in the coverage gap. This study is one of only a few to examine health 
plan data while the coverage gap is closing due to the ACA and the only one to cover six 
years.  
The study design accounts for different types of effects that can introduce biases 
in our estimates. First, in assessing objective 1 (medication adherence rates during the 
gap), eligible health plan members were used as their own controls. Since the same 
cohort of patients is observed before and after the intervention, this reduces potential bias 
introduced due to differences in beneficiary characteristics between the study periods. 
Second, this study used the pre-post-with-a-comparison-group design to assess objectives 
2 and 3, the strongest quasi-experiment observational study design. The benefit to this 
81	  
approach was that the drug coverage in the control group did not change in the pre-gap 
and within-gap periods, while treatment groups were exposed to a sudden increase in 
medication price. Even though the control group was different in socioeconomic status 
from the treatment groups, all groups had similar baseline trends in diabetic medication 
use. 
The study is not without limitations. The use of retrospective claims data implies 
that the study is affected by limitations related to secondary data sources. One significant 
limitation is the assumption that filled prescriptions were taken as prescribed. Another 
limitation of claims data is the lack of visibility into physician dispensed samples or cash 
prescriptions. This study was limited to only one health plan, although the health plan had 
the second largest national share of Medicare Part D membership during the study period. 
This study was also limited to health plan members using diabetic medications at 
Humana’s mail order facility and therefore may not generalize to the broader population. 
 
Findings and recommendations for future research 
The results of this study indicate that being in the coverage gap was a significant 
indicator of a decrease in adherence for health plan members on brand diabetic 
medications. This was apparent when evaluating pre-gap versus within-gap adherence 
and when the cohort was compared to a control group. Although the generic cohort did 
not show significant differences for all years, the cohort did show a decrease in adherence 
while in the coverage gap. Both cohorts also exhibited a decrease in the difference 
between pre-gap verses within-gap adherence from 2009 to 2014, which could indicate 
the closing of the coverage gap is beginning to have an effect on within-gap behavior. In 
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other words, in later years health plan members had a less significant drop in adherence 
rates once they entered the coverage gap and this could be due to the ACA lessening the 
impact of the coverage gap. 
While the study findings showed a decrease rather than an increase in the 
treatment group medication adherence year over year, the results did indicate no 
significant changes in the control group. The expectation would be that once the coverage 
gap is fully closed in 2020, the treatment group would exhibit similar behavior.  Both 
groups exhibited high adherence overall suggesting the mail order dispensing channel 
could have an effect on adherence. 
Limiting the population to mail order utilizers was an unintended potentially 
important variable in this study. Studies have shown that mail order utilizers have 
considerably higher adherence than health plan members who utilize retail pharmacies. 
One reason for higher adherence at mail order could be the automatic refill option 
available at many mail order pharmacies where refills are shipped without the health plan 
member requesting it. This could result in an inflated adherence rate because the 
medication is shipped whether the member needs it or not. It should be noted that 
Humana’s mail order pharmacy does not offer automatic refills for Medicare Part D 
members. They do have reminder calls but the health plan member must take some action 
on their part and opt in to order a refill.  
Because dispensing channel was an unintended variable, it was not included in the 
theoretical model discussion, specifically Andersen’s Behavioral Model. In the model, 
enabling resources are factors that support or impede the use of health services. For 
example, the type of health insurance is considered an enabling resource. Dispensing 
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channel would be classified as an enabling resource in the model considering it affects 
the method by which a health plan member accesses their medication. It would be 
considered a highly mutable factor because it can be changed from a retail pharmacy to 
mail order or even to a physician office or hospital. 
Future research should examine the effect of the coverage gap once it is fully 
closed in 2020 and it is possible to take an even broader view of the coverage gap impact. 
As evidence from the literature suggests, decreases in medication adherence can result in 
poor clinical outcomes, which can increase the total cost of care. Therefore, in addition to 
adherence, future research should be directed at studying the impact of the Medicare Part 
D coverage gap on utilization of other health care services like diagnostic tests, physician 
office utilization, emergency room visits and hospitalizations. Finally, more attention 
should be given to the dispensing channel and it’s possible effect on medication 
adherence. Future research should focus on whether mail order utilization promotes better 
medication adherence or if better adherers choose mail order. 
 
Summary 	   This	  study	  is	  important	  and	  relevant	  because	  it	  is	  one	  of	  the	  only	  studies	  identified	  that	  utilized	  6	  years	  of	  data	  related	  to	  the	  closing	  of	  the	  coverage	  gap.	  While	  the	  results	  failed	  to	  show	  the	  closing	  of	  the	  coverage	  gap	  as	  having	  an	  impact	  on	  improving	  adherence	  in	  this	  group	  over	  multiple	  years,	  it	  was	  determined	  that	  entering	  the	  coverage	  gap	  decreased	  adherence	  and	  the	  additional	  cost	  pressures	  in	  the	  form	  of	  increasing	  coverage	  limits	  and	  price	  inflation	  may	  have	  offset	  any	  good	  closing	  the	  coverage	  gap	  is	  doing	  in	  these	  diabetic	  patients.	  This	  study	  also	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highlights	  the	  complexity	  of	  medication	  adherence	  and	  the	  need	  for	  additional	  research	  in	  this	  area.	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Coverage gap: A benefit phase in Medicare Part D where the enrollee incurs all or most 
of the drug cost until they hit a certain coverage limit  
 
Low-income subsidy (LIS): Medicare beneficiaries who qualify for assistance in paying 
for their Part D monthly premium, annual deductible, coinsurance, and copayments 
 
Medicare Advantage prescription drug plan (MAPD): a drug benefit offered as part of 
a Medicare replacement plan 
 
Medicare Modernization Act (MMA): Legislation passed in 2003 allowing Medicare 
expansion in 2006 to offer voluntary outpatient prescription drug coverage 
 
Pharmacy Quality Alliance (PQA): A consensus-based, multi-stakeholder membership 
organization committed to improving health care quality and patient safety with a focus 
on the appropriate use of medications 
 
Prescription drug plan (PDP): A drug benefit offered as a supplement to standard 
Medicare  
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Propensity score matching (PSM): A statistical matching technique that attempts to 
estimate the effect of a treatment, policy or other intervention by accounting for the 
covariates that predict receiving the treatment 
 
Proportion of days covered (PDC): A measurement period covered by prescription 
claims for the same medication or another in its therapeutic category 
 
True-out-of-pocket-spending (TrOOP): Only costs incurred and paid by the health plan 
member, those prescription drug costs that count toward the annual out- of-pocket 
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